Nuritas announces formation of Scientific Advisory Board

Biotech, Business | Tue 9 Oct | Author – Business & Finance
Dr Nora Khaldi
Nuritas founder and CSO Nora Khaldi

Nuritas, a biotechnology company discovering life-changing drugs through the power of artificial intelligence (AI) based peptide discovery, announced the formation of its scientific advisory board (SAB)

“We are delighted to have attracted some of the world’s leading experts in drug discovery, metabolism, immunology, food for health, proteomics and molecular diagnostics to support Nuritas as we advance our AI platform and bioactive peptide discovery to address the world’s growing healthcare needs,” said Emmet Browne, chief executive officer of Nuritas. He continued:

The formation of our SAB serves to further strengthen Nuritas’s unique approach to discover peptide-based therapies with unmatched speed and accuracy.

Dr. Nora Khaldi, Ph.D., founder and chief scientific officer of Nuritas said,

The scientific guidance of this group of experts will be key as we accelerate and develop our unique peptide discoveries to improve human health. We are continuing to expand our scientific teams at Nuritas and the addition of the SAB further strengthens this.

About Nuritas and founder Dr Khaldi

Founded in 2014, Nuritas develops preventative and curative peptide-based treatments for disease using a proprietary artificial intelligence (AI) platform, with in silico predictions validated by their in-house multidisciplinary team of scientists and laboratory.

Nuritas has received global recognition for the impact of its innovative technology which includes winning the overall Innovation Award at the Forbes Reinventing America Summit in 2015, the Nutrition Capital Network Venture competition in October 2016 and support from EU Horizon 2020 in 2016 for a peptide that carries the potential to prevent pre-diabetic patients from developing diabetes. Dr Nora Khaldi will be honoured at Business & Finance’s CEO100 in October this year.